ESR1 and invasive ductal breast carcinoma: Next, we investigated the clinical relevance of the different gene signatures identified from microarray analysis, by using the clinically available Metabric cohort comprising 1980 tumor samples, composed in the majority of ERα-positive invasive ductal carcinoma (Figure 5B) [34].